China Oncology ›› 2019, Vol. 29 ›› Issue (2): 142-147.doi: 10.19401/j.cnki.1007-3639.2019.02.008

Previous Articles     Next Articles

Comparative study on the pathological features of BRCA1/2 mutation and non-BRCA1/2 mutation breast cancers in China

ZHU Xinyi1, TIAN Tian2, CAI Xu2, QIN Guangqi3, SUN Menghong3, WU Jiong1, SHEN Zhenzhou1, SHAO Zhimin1, HU Zhen1   

  1. 1.Breast Cancer Institute, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 3. Tissue Bank, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Online:2019-02-28 Published:2019-03-25
  • Contact: HU Zhen E-mail: zhenhu@fudan.edu.cn

Abstract: Background and purpose: BRCA1 and BRCA2 are two most common genes associated with hereditary breast cancers. Our research intended to discover the pathologic features of Chinese breast cancers with BRCA1/2 mutations. Methods: We included 287 breast cancers between 2011 and 2017, and BRCA1/2 germline mutation tests were carried out. The pathologic features of each patient were collected at Department of Pathology in Fudan University Shanghai Cancer Center for comparative study. Results: Of the 287 breast cancers, 66 cases were BRCA1 mutation positive, 47 cases were BRCA2 mutation positive and 174 cases were BRCA1/2 mutation negative. BRCA1 mutation breast cancer had higher nuclear grade tumors than the other two groups (P<0.001), 72.7% of BRCA1 mutation breast cancers were, whereas 25.5% of BRCA2 and 19.0% of non-BRCA1/2 mutation breast cancers were triple negative (P<0.001). BRCA1 and BRCA2 mutated breast cancers had lower human epidermal growth factor receptor 2(HER2) expression than non-BRCA1/2 mutated breast cancers (P<0.001). The positive expressions of cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor (EGFR) in BRCA1 mutation breast cancer were about 50%, significantly higher than those of the other two groups (P<0.001), and androgen receptor (AR) positive was less frequently seen in BRCA1 mutation breast cancers. Conclusion: These results suggest that BRCA1 mutation-associated breast cancers had clinical pathologic characteristics, such as triple negative, more positive CK5/6 or EGFR status. BRCA1/2 mutated breast cancers had lower HER2 expression.

Key words: BRCA1 gene, BRCA2 gene, Breast cancer, Pathology